# Shanghai Zhiyu Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-zhiyu-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $14M
- Latest round: Series A (May 25, 2023)
- Investors on record: 6

## About

Established in 2021 and based in Shanghai, China, The company has built a complete protein structure prediction, design, and production system on its own to carry out drug-assisted R&D and synthetic biology business. Dr. Sheng Wang, CEO of the company, is a top global scholar in the field of artificial intelligence combined with protein research and was a senior research expert at Tencent AI Lab. Doctors from the Chinese Academy of Sciences, CSU, and other research institutions jointly participate in the company's team project development, in addition to academic research support and cooperation support from academic leaders from the University of Hong Kong-China, Fudan, and Chinese Academy of Sciences. In May 2023, it raised over CNY 100 million in series A funding led by new investor Hongjia Asset Management, with participation from other new investors Hangzhou Qiantang Zhiyong Venture Capital Partnership (Limited Partnership), HM Capital, and Hongfeng Investment.

The company has built a service platform for protein structure prediction and design and related applications, including single-sequence protein structure prediction, multi-sequence protein complex structure prediction, protein-ligand binding energy prediction, protein structure design, and sequence design, protein complex interaction design, protein stability modification, and other services. Based on big data and AI protein structure prediction and protein-ligand binding energy calculation and optimization, the company has completed 30W+ protein structure prediction and R&D assistance services for nearly 30 customers. Specific products include ZCloud, a protein structure prediction, and R&D aid facility; ZPod, a one-stop engineering solution for protein structure calculation and ZBot, a high-throughput automated wet experiment platform.

In the future, the company's service platform will also include new services for drug development such as fully automated high-throughput virtual screening, structure-based small molecule generation, fully automated high-performance free energy perturbation, and small molecule property prediction.

## Funding rounds

- Series A, May 25, 2023, $14M — Hongjia Asset Management, HM Capital, Hongfeng Venture, Hangzhou Qiantang Zhiyong Venture Capital Partnership (Limited Partnership)
- Angel, Jun 15, 2021 — CDH Investments, Laurel Venture

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Angel
- Laurel Venture (https://capitalatlas.ai/funds/laurel-venture) — Angel
- Hongjia Asset Management — Series A
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series A
- Hongfeng Venture (https://capitalatlas.ai/funds/hongfeng-venture) — Series A
- Hangzhou Qiantang Zhiyong Venture Capital Partnership (Limited Partnership) — Series A